목적: 증식성 당뇨망막병증에서 발생한 신생혈관의 치료로 Bevacizumab을 유리체 강내 주사시 효과를 알아보았다. 대상과 방법: 활동성 신생혈관을 보이는 증식성 당뇨망막병증 환자 19명 20안을 대상으로 전향적 연구를 시행하였다. 1.25 mg Bevacizumab을 유리체강내 주사 후 시술 전, 시술 1주, 4주, 8주 후에 최대교정시력의 변화, 형광안저혈관조영에서 신생혈관의 범위를 조사하였다. 결과: 남자 12명(63.2%), 여자 7명(36.8%)의 20안을 대상으로 평균나이는 47.05±12.48세였다. 시술 전 신생혈관의 범위는 23.02± 21.80 mm², 시술 1주, 4주, 8주 후에 4.96±9.18 mm², 1.11±4.96 mm², 4.55±5.11 mm²로 통계적으로 유의한 감소를 보였다(p<0.05). 시술 4주째 19안에서 신생혈관 범위 감소를 관찰했다. 평균최대교정시력(logMAR)은 시술 전 0.59±0.49, 시술 1주, 4주, 8주 후 0.56±0.47, 0.55±0.73, 0.51±0.50로 호전을 보였다. 결론: Bevacizumab 유리체강내 주사는 증식성 당뇨망막병증 후 발생한 신생혈관의 감소효과를 보였다.

Purpose: To evaluate the short-term effects of a single intravitreal injection of bevacizumab (Avastin) for the management of new vessels (NV) associated with proliferative diabetic retinopathy (PDR). Methods: A non-randomized study of 19 PDR patients (20 eyes) who had active NV was analyzed prospectively. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 4, and 8 after intravitreal injection of 1.25 mg of bevacizumab. The main outcome measures included changes in total area of fluorescein leakage from active NV and best corrected visual acuity (BCVA). Results: Twenty eyes of 19 patients (12 men [63.2%], 7 women [36.8%]) were included and all patients completed the 8-week study follow-up period. The mean age of participants was 47.05±12.48 years. At baseline, NV area was 23.02±21.80 mm2. The area of active NV decreased significantly to 4.96±9.18 mm², 1.11±4.96 mm² and 4.55±5.11 mm² (p<0.05) at 1, 4 and 8 weeks after injection, respectively. At week 4, no leakage was observed in 19 eyes. The mean logMAR BCVA improved from 0.59±0.49 at baseline to 0.56±0.47, 0.55±0.73 and 0.51±0.50 at weeks 1, 4, and 8, respectively. No significant adverse events were observed. Conclusions: Short-term results suggest that intravitreal injection of bevacizumab is associated with a rapid regression of retinal neovascularization secondary to PDR.

Purpose: To evaluate the short-term effects of a single intravitreal injection of bevacizumab (Avastin) for the management of new vessels (NV) associated with proliferative diabetic retinopathy (PDR). Methods: A non-randomized study of 19 PDR patients (20 eyes) who had active NV was analyzed prospectively. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 4, and 8 after intravitreal injection of 1.25 mg of bevacizumab. The main outcome measures included changes in total area of fluorescein leakage from active NV and best corrected visual acuity (BCVA). Results: Twenty eyes of 19 patients (12 men [63.2%], 7 women [36.8%]) were included and all patients completed the 8-week study follow-up period. The mean age of participants was 47.05±12.48 years. At baseline, NV area was 23.02±21.80 mm2. The area of active NV decreased significantly to 4.96±9.18 mm², 1.11±4.96 mm² and 4.55±5.11 mm² (p<0.05) at 1, 4 and 8 weeks after injection, respectively. At week 4, no leakage was observed in 19 eyes. The mean logMAR BCVA improved from 0.59±0.49 at baseline to 0.56±0.47, 0.55±0.73 and 0.51±0.50 at weeks 1, 4, and 8, respectively. No significant adverse events were observed. Conclusions: Short-term results suggest that intravitreal injection of bevacizumab is associated with a rapid regression of retinal neovascularization secondary to PDR.